Diabetic metastatic castration resistant prostate cancer patients administered mefformin during docetaxel chemotherapy have improved prostate cancer-specific and overall survival

被引：1
|
作者：
Mayer, Michelle
Klotz, Laurence
Venkateswaran, Vasundara
机构：
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.AM2016-1434
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1434
引用
收藏
页数：4
相关论文
共 50 条
  • [11] Docetaxel rechallenge chemotherapy in metastatic castration-resistant prostate cancer (mCRPC).
    Bracarda, S.
    Sisani, M.
    Rossi, M.
    Galli, L.
    Hamzaj, A.
    Scali, S.
    De Angelis, V.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [12] Prostate-specific antigen testing in men with metastatic castration-resistant prostate cancer treated with docetaxel chemotherapy
    Tsai, Yuh-Shyan
    Tzai, Tzong-Shin
    UROLOGICAL SCIENCE, 2015, 26 (04) : 277 - 277
  • [13] PROGNOSTIC FACTORS FOR OVERALL SURVIVAL IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER TREATED BY INTERMITTENT CHEMOTHERAPY WITH DOCETAXEL AND PREDNISOLONE
    Narita, Shintaro
    Koie, Takuya
    Yamada, Shigeyuki
    Orikasa, Kazuhiko
    Matsuo, Shigeki
    Aoki, Hiroshi
    Ishidoya, Shigeto
    Hoshi, Senji
    Tsuchiya, Norihiko
    Ohyama, Chikara
    Arai, Yoichi
    Habuchi, Tomonori
    JOURNAL OF UROLOGY, 2015, 193 (04): : E1086 - E1087
  • [14] Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
    Kreis, Kristine
    Horenkamp-Sonntag, Dirk
    Schneider, Udo
    Zeidler, Jan
    Glaeske, Gerd
    Weissbach, Lothar
    BJU INTERNATIONAL, 2022, 129 (04) : 470 - 479
  • [15] Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC)
    Charles J. Ryan
    Sandipan Dutta
    William K. Kelly
    Carly Russell
    Eric J. Small
    Michael J. Morris
    Mary-Ellen Taplin
    Susan Halabi
    Prostate Cancer and Prostatic Diseases, 2020, 23 : 66 - 73
  • [16] Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC)
    Ryan, Charles J.
    Dutta, Sandipan
    Kelly, William K.
    Russell, Carly
    Small, Eric J.
    Morris, Michael J.
    Taplin, Mary-Ellen
    Halabi, Susan
    PROSTATE CANCER AND PROSTATIC DISEASES, 2020, 23 (01) : 66 - 73
  • [17] Docetaxel based chemotherapy in the treatment of patients with castration resistant prostate cancer
    Mangir, N.
    Turkeri, L.
    ACTAS UROLOGICAS ESPANOLAS, 2014, 38 (08): : 515 - 522
  • [18] The Effect of Time to Castration Resistance on Overall Survival and Success of Docetaxel Treatment in Castration Resistant Prostate Cancer Patients
    Suer, Evren
    Hamidi, Nurullah
    Akpinar, Cagri
    Gokce, Mehmet Ilker
    Gulpinar, Omer
    Turkolmez, Kadir
    Beduk, Yasar
    Baltaci, Sumer
    UROLOGY JOURNAL, 2019, 16 (05) : 453 - 457
  • [19] Impact of Serum γ-Glutamyltransferase on Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Docetaxel
    Une, Minami
    Takemura, Kosuke
    Inamura, Kentaro
    Fukushima, Hiroshi
    Ito, Masaya
    Kobayashi, Shuichiro
    Yuasa, Takeshi
    Yonese, Junji
    Board, Philip G.
    Koga, Fumitaka
    CANCERS, 2021, 13 (21)
  • [20] The effect of therapeutic anticoagulation on overall survival (OS) in men receiving docetaxel chemotherapy for metastatic castration-resistant prostate cancer (mCRPC)
    Pratz, Caroline F.
    Brodsky, Robert A.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345